NO991096L - Nye fremgangsmÕter - Google Patents

Nye fremgangsmÕter

Info

Publication number
NO991096L
NO991096L NO991096A NO991096A NO991096L NO 991096 L NO991096 L NO 991096L NO 991096 A NO991096 A NO 991096A NO 991096 A NO991096 A NO 991096A NO 991096 L NO991096 L NO 991096L
Authority
NO
Norway
Prior art keywords
new procedures
idoxifene
treatment
cardiovascular disease
new method
Prior art date
Application number
NO991096A
Other languages
English (en)
Norwegian (no)
Other versions
NO991096D0 (no
Inventor
Jeremy N Bradbeer
Maxine Gowen
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO991096D0 publication Critical patent/NO991096D0/no
Publication of NO991096L publication Critical patent/NO991096L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO991096A 1996-09-06 1999-03-05 Nye fremgangsmÕter NO991096L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2543996P 1996-09-06 1996-09-06
US5066697P 1997-06-24 1997-06-24
PCT/US1997/015475 WO1998009619A1 (en) 1996-09-06 1997-09-03 Novel methods

Publications (2)

Publication Number Publication Date
NO991096D0 NO991096D0 (no) 1999-03-05
NO991096L true NO991096L (no) 1999-03-05

Family

ID=26699738

Family Applications (2)

Application Number Title Priority Date Filing Date
NO991096A NO991096L (no) 1996-09-06 1999-03-05 Nye fremgangsmÕter
NO991097A NO991097L (no) 1996-09-06 1999-03-05 Nye fremgangsmÕter

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO991097A NO991097L (no) 1996-09-06 1999-03-05 Nye fremgangsmÕter

Country Status (16)

Country Link
EP (2) EP0929216A4 (cs)
JP (2) JP2002515046A (cs)
KR (2) KR20000068473A (cs)
CN (2) CN1236299A (cs)
AR (1) AR008155A1 (cs)
AU (2) AU4409797A (cs)
BR (2) BR9711681A (cs)
CA (2) CA2264775A1 (cs)
CO (2) CO5070658A1 (cs)
CZ (1) CZ76699A3 (cs)
IL (1) IL128645A0 (cs)
NO (2) NO991096L (cs)
PL (2) PL332038A1 (cs)
TR (2) TR199900506T2 (cs)
TW (1) TW411273B (cs)
WO (2) WO1998009619A1 (cs)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998034608A1 (en) * 1997-02-11 1998-08-13 Novo Nordisk A/S Methods for treatment or prophylaxis of menopausal symptoms
GB9827121D0 (en) * 1998-12-09 1999-02-03 Orion Corp Agent for lowering endothelin levels
DE19905961A1 (de) * 1999-02-12 2000-08-17 Stefan Neubauer Verwendung von Östrogenen zur Behandlung der Herzinsuffizienz
US6528681B2 (en) * 2000-04-05 2003-03-04 Bristol-Meyers Squibb Pharma Company Halogenated triphenylethylene derivatives as selective estrogen receptor modulators
IL145876A0 (en) 2000-10-17 2002-07-25 Pfizer Prod Inc Methods and kits for improving vascular health

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3762617D1 (de) * 1986-09-11 1990-06-13 Nat Res Dev Tamoxifenderivate.
FI951193L (fi) * 1992-09-15 1995-03-14 Merrell Pharma Inc Ei-metabolisoituvat klomifeenianalogit tamoksifeeniresistenttien kasvainten hoitamiseksi
US5681835A (en) * 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5604248A (en) * 1994-05-05 1997-02-18 Eli Lilly And Company Method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs
US5470883A (en) * 1994-05-23 1995-11-28 Stromberg; Brent V. Method of treating peripheral vasoconstriction with tamoxifen citrate
CA2223595C (en) * 1995-06-07 2008-08-05 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
US6069175A (en) * 1996-11-15 2000-05-30 Pfizer Inc. Estrogen agonist/antagonists treatment of atherosclerosis

Also Published As

Publication number Publication date
EP0929216A4 (en) 2001-04-04
PL332038A1 (en) 1999-08-16
AR008155A1 (es) 1999-12-09
JP2002515046A (ja) 2002-05-21
EP0929216A1 (en) 1999-07-21
IL128645A0 (en) 2000-01-31
WO1998009519A1 (en) 1998-03-12
CA2264943A1 (en) 1998-03-12
NO991097D0 (no) 1999-03-05
JP2002515047A (ja) 2002-05-21
CN1236299A (zh) 1999-11-24
PL332278A1 (en) 1999-08-30
TW411273B (en) 2000-11-11
TR199900504T2 (xx) 1999-06-21
CA2264775A1 (en) 1998-03-12
KR20000068473A (ko) 2000-11-25
AU4409797A (en) 1998-03-26
BR9711681A (pt) 1999-08-24
TR199900506T2 (xx) 1999-07-21
NO991096D0 (no) 1999-03-05
AU4247397A (en) 1998-03-26
CN1236313A (zh) 1999-11-24
WO1998009619A1 (en) 1998-03-12
BR9711676A (pt) 1999-08-24
CZ76699A3 (cs) 1999-08-11
CO4920218A1 (es) 2000-05-29
KR20000068472A (ko) 2000-11-25
CO5070658A1 (es) 2001-08-28
NO991097L (no) 1999-03-05
EP0927029A1 (en) 1999-07-07
EP0927029A4 (en) 2001-06-13

Similar Documents

Publication Publication Date Title
NO993247D0 (no) FremgangsmÕte for fremstilling av tolterodin
NO179250C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktiv (+)--(2,3-dimetoksyfenyl)-1-[2-(4-fluorfenyl)etylÅ-4-piperidinmetanol
PL332432A1 (en) Oxadiazoles, method of obtaining them as well as their application as therapeutic agents
ES2172587T3 (es) Composicion que comprende morfina, polipirrolidona y poli-oxido de alquileno.
NO20075065L (no) Anvendelse av isoflavonforbindelser til a behandle hjertesykdom
DE69735367D1 (de) THERAPEUTISCHE MULTISPEZIFISCHE VERBINDUNGEN, DIE ANTIKÖRPER GEGEN DEN FCalpha-REZEPTOR ENTHALTEN
BG101949A (bg) Диспергируема частичкова система за десензибилизиране на зъби
NO991096L (no) Nye fremgangsmÕter
NO901383D0 (no) Maskin for automatisk anbringelse av myk pakning.
ZA9783B (en) Novel medical use
SE9501881D0 (sv) New pharmacological use of AII-receptor antagonists
DE59709922D1 (de) Pflaster zur transdermalen anwendung von pergolid
NO990914L (no) Amorfe benzotiofener, fremgangsmÕter for fremstilling og fremgangsmÕter for anvendelse
ATE229326T1 (de) Therapie von depressionen
NO984245L (no) Nasal administrasjon av midler for behandling av emesis med forsinket begynnelse
DE69736180D1 (de) Behandlung von manischen erkrankungen
DE69729201T2 (de) Sulfonfluoride zur behandlung von der alzheimerischen krankheit
NO20000961L (no) Nye vevs-spesifikke calpainer, samt fremgangsmåte for fremstilling og anvendelse derav
FR2759906B1 (fr) Utilisation de milnacipran et de ses derives pour la preparation d'un medicament destine au traitement de certaines maladies psychiatriques
ATE226825T1 (de) Behandlung der anorexie
DE3865675D1 (de) 1-((2-fluorophenyl)(4-fluorophenyl)phenylmethyl)-1h-imidazol.
NO990436L (no) FremgangsmÕte for behandling av bipolar forstyrrelse
SE9500897D0 (sv) The pharmacological use of certain cystine derivatives
NO20006382L (no) Fremgangsmåte for behandling av organofosfatforgiftning
SE9404438D0 (sv) New process

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application